Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
EG.1.8NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
EG.1.8NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.5.49NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
XBB.1.5.49NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBL.1NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
XBL.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FR.1NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
FR.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FL.17NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
FL.17NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.2.3NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
XBB.2.3NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FL.18.1NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
FL.18.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FL.15NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
FL.15NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
EG.14NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
EG.14NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-22683US
FL.14NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
FL.14NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.2.3.12NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
XBB.2.3.12NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.16.21NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
XBB.1.16.21NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.568NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.568NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
P.1.13 (Gamma)NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
P.1.13 (Gamma)NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.1.372NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.1.372NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.634NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.634NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
C.37.1NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
C.37.1NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.630NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.630NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.360NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.360NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.578NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.578NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.544NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.544NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26650.4US
B.1.448NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.448NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
B.1.425NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
B.1.425NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.9NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
XBB.1.42NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
XBB.1.42NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-26482.3US
FL.4.10NSC2CTGCAGATTTGGATGATTTCTCC2343.482946329485F-23117.2US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used